Treatment Access

AHC calls for the Provinces and Territories to:
 - continue to develop population-specific strategies and dedicate resources to overcome the barriers that many Canadians still face regarding diagnosis and treatment: waitlists, geographical/ socio-economical/ cultural challenges; 
 - increase capacity among healthcare practitioners for treatment; 
 - include re-treatments in reimbursement formularies.

2014
Multiple DAA medications were approved by Health Canada and came to the Canadian market with high curative rates, reduced side effects, and shorter treatment durations.

2015
CADTH (Canadian Agency for Drugs and Technology in Health) recommended the DAAs be listed, but with conditions of a fibrosis score of F2 or higher, to help control costs, and most provinces added the DAAs to their formularies with these recommended restrictions.  AHC wrote a position paper calling for universal access, hosted a breakfast in the Ontario Legislature to educate elected officials on policy alternatives, met with MPPs in Ontario and provided tools for members to engage their own provincial elected officials.

2016
AHC and our allies urged CADTH to drop the F2 or greater restrictions, which they did. We then wrote to all provincial health ministries to make sure they were aware of the change. We also helped draft the Greater Access to Hepatitis C Treatment Act by an Ontario MPP, and assisted Yukon’s Health Critic in raising the issue during Question Period.

2017
In February 2017, the pan-Canadian Pharmaceutical Alliance announced that they had negotiated a much better price for DAA hepatitis C medications, and as a result, several provinces announced that they would update their formularies and begin lowering their eligibility restrictions. Ontario and BC also announced that they would be moving to no restrictions based on fibrosis levels by 2018-2019. The AHC will continue to engage decision makers in the provinces and territories that have not yet updated their formularies, to  increase access to DAA medications for all Canadians diagnosed with chronic hepatitis C.

2018
In February/March of 2018, Ontario, BC, Quebec, and the NIHB formularies were all updated, joining PEI in lifting all fibrosis restrictions for treatment of hepatitis C. In April we saw Alberta, Saskatchewan, Manitoba, and the Yukon lift all fibrosis restrictions as well, with New Brunswick and Nova Scotia following in May, and Newfoundland followed soon after. Now all that is needed is a diagnosis of chronic hepatitis C.

​This is a very big step for equal access to treatment! However, barrier still exist as increased eligibility has not resulted in an increased capacity for treatment.